AMGEN, INC. for AMGEN INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act HR 830 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 1613 to amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to clinical trial diversity Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B (PROTECT 340B act of 2023) Issues related to pharmacy benefits managers
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| WINTA MENGHIS | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Medicare/Medicaid MMM
Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act HR 485 Protecting Health Care for All Patients Act HR 1613 To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| WINTA MENGHIS New | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JORDAN LYNN LAYSON | — |
| HOWARD MOON | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Copyright/Patent/Trademark CPT
S. 79 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to march-in/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to false claims act Issues related to FDA/PTO coordination Issues related to patent thickets/product hopping
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| KIMBERLY LOVE | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.